Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
GeneFerm Biotechnology CoROCO:1796 -1.26%65 Gross Margin % is 31.84% as of Dec. 2025, which is 7% below its 10-year median of 34.08. GuruFocus rates ROCO:1796 with a GF Score™ of 65/100 and a GF Value™ of NT$59.04 (Significantly Undervalued). The stock has 6 warning signs investors should review. Among 941 Drug Manufacturers companies, GeneFerm Biotechnology Co ranks worse than 82.78% on this metric.
GeneFerm Biotechnology Co (ROCO:1796) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
GeneFerm Biotechnology Co had a gross margin of 31.84% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
GeneFerm Biotechnology Co Gross Margin % Related Terms
GeneFerm Biotechnology Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, GeneFerm Biotechnology Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
GeneFerm Biotechnology Co Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, GeneFerm Biotechnology Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where GeneFerm Biotechnology Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
GeneFerm Biotechnology Co (ROCO:1796) has a Gross Margin % of 31.84% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on GeneFerm Biotechnology Co and its competitors. This is near median its historical median of 34.08. Over the past decade, GeneFerm Biotechnology Co's Gross Margin % has ranged from 18.56 to 49.98. According to the industry distribution chart, GeneFerm Biotechnology Co ranks #779 out of 941 companies in the Drug Manufacturers industry, placing it in the top 82.8%.
Is GeneFerm Biotechnology Co's Gross Margin % too high?
GeneFerm Biotechnology Co's current Gross Margin % of 31.84% is near median its 10-year median of 34.08. Over the past 10 years, this metric has ranged from a low of 18.56 to a high of 49.98. The Drug Manufacturers industry median Gross Margin % is 48.54. GeneFerm Biotechnology Co's value of 31.84% is 34.4% below this industry median. Based on the distribution chart, GeneFerm Biotechnology Co ranks #779 out of 941 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, GeneFerm Biotechnology Co has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GeneFerm Biotechnology Co's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, GeneFerm Biotechnology Co ranks #779 out of 941 companies for Gross Margin %. This places GeneFerm Biotechnology Co in the lower half of its industry. The industry median Gross Margin % is 48.54. GeneFerm Biotechnology Co's value of 31.84% is 34.4% below this benchmark. Historically, GeneFerm Biotechnology Co's own Gross Margin % has ranged from 18.56 to 49.98 over the past decade. While the company's 10-year median is 34.08 vs. the industry median of 48.54, GeneFerm Biotechnology Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 941 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GeneFerm Biotechnology Co's current Gross Margin % of 31.84% is 34.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on GeneFerm Biotechnology Co and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GeneFerm Biotechnology Co's current Gross Margin % is 31.84%, which is near median its own 10-year median of 34.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneFerm Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, GeneFerm Biotechnology Co (ROCO:1796) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$59.04, compared to a current price of NT$31.40 — trading 46.8% below its estimated fair value. The current Gross Margin % is 31.84%, which is near median its 10-year median of 34.08 and 34.4% below the Drug Manufacturers industry median of 48.54. GeneFerm Biotechnology Co's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For GeneFerm Biotechnology Co (ROCO:1796), the current Gross Margin % is 31.84% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is GeneFerm Biotechnology Co (ROCO:1796) Overvalued in 2026?
Based on GuruFocus' analysis, GeneFerm Biotechnology Co stock appears to be undervalued.
The current stock price of NT$31.40 is trading 46.8% below its estimated GF Value™ of NT$59.04.
GuruFocus considers GeneFerm Biotechnology Co to be Significantly Undervalued.
Key valuation signals for ROCO:1796:
Gross Margin %: 31.84% (near median its 10-year median of 34.08)
GF Value™: NT$59.04 vs. price of NT$31.40 (46.8% below fair value)
Industry Position: 34.4% below the Drug Manufacturers median (#779 of 941)
No single metric tells the full story. See the ROCO:1796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GeneFerm Biotechnology Co Ltd is a fermentation company based in Taiwan. It is engaged in manufacturing health food and supplements which include Fermented Microbial products, Fermented Fungi products, Probiotics and Extraction, and Concentration products among others.
65GF Score
Get the complete analysis for ROCO:1796
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1796 has been successfully added to your 
